The store will not work correctly when cookies are disabled.
7-chloro-8-methyl-3-[1-(2,2,3,3,3-pentafluoropropyl)pyrazol-4-yl]-2-(trifluoromethyl)pyrido[1,2-a]pyrimidin-4-one
ID: ALA4879015
PubChem CID: 156409362
Max Phase: Preclinical
Molecular Formula: C16H9ClF8N4O
Molecular Weight: 460.71
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: Cc1cc2nc(C(F)(F)F)c(-c3cnn(CC(F)(F)C(F)(F)F)c3)c(=O)n2cc1Cl
Standard InChI: InChI=1S/C16H9ClF8N4O/c1-7-2-10-27-12(15(20,21)22)11(13(30)29(10)5-9(7)17)8-3-26-28(4-8)6-14(18,19)16(23,24)25/h2-5H,6H2,1H3
Standard InChI Key: CZIUPLPUVPKKLP-UHFFFAOYSA-N
Molfile:
RDKit 2D
30 32 0 0 0 0 0 0 0 0999 V2000
17.8379 -19.4558 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
17.4334 -20.1656 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.2504 -20.1610 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
13.8991 -18.9398 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.8979 -19.7594 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.6060 -20.1683 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.6042 -18.5310 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.3128 -18.9362 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
15.3117 -19.7569 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.0179 -20.1659 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
16.7297 -19.7589 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.7309 -18.9382 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.0202 -18.5246 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.0202 -17.7074 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
17.4340 -20.9866 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
17.4375 -18.5304 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.1833 -18.8645 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.7315 -18.2585 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
18.3246 -17.5498 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
17.5249 -17.7179 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.1913 -18.5314 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
19.5440 -18.3459 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.0260 -17.6860 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.8385 -17.7733 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.3204 -17.1134 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
20.8343 -18.5890 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
21.5441 -18.1804 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
19.4434 -17.1032 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
20.2358 -16.8927 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
13.1899 -20.1674 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 0
3 2 1 0
4 5 1 0
5 6 2 0
6 9 1 0
8 7 1 0
7 4 2 0
8 9 1 0
8 13 1 0
9 10 2 0
10 11 1 0
11 12 2 0
12 13 1 0
13 14 2 0
11 2 1 0
2 15 1 0
16 17 2 0
17 18 1 0
18 19 1 0
19 20 2 0
20 16 1 0
12 16 1 0
4 21 1 0
18 22 1 0
22 23 1 0
23 24 1 0
24 25 1 0
24 26 1 0
24 27 1 0
23 28 1 0
23 29 1 0
5 30 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 460.71 | Molecular Weight (Monoisotopic): 460.0337 | AlogP: 4.74 | #Rotatable Bonds: 3 |
Polar Surface Area: 52.19 | Molecular Species: NEUTRAL | HBA: 5 | HBD: ┄ |
#RO5 Violations: ┄ | HBA (Lipinski): 5 | HBD (Lipinski): ┄ | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: ┄ | CX Basic pKa: 1.41 | CX LogP: 3.84 | CX LogD: 3.84 |
Aromatic Rings: 3 | Heavy Atoms: 30 | QED Weighted: 0.53 | Np Likeness Score: -1.26 |
References
1. Sabnis RW.. (2021) Novel Heterocyclic Compounds as Delta-5-Desaturase Inhibitors for Treating Metabolic and Cardiovascular Diseases., 12 (8.0): [PMID:34413950] [10.1021/acsmedchemlett.1c00394] |